4DMedical Ltd ( (AU:4DX) ) has provided an update.
4DMedical Limited has received regulatory approval for its CT Lung Ventilation Analysis Software (CT LVAS™) in Canada, enhancing its portfolio of respiratory imaging products in the region. This approval allows 4DMedical to expand its presence in the Canadian healthcare market, which is significantly larger than Australia’s, and positions the company for future growth and potential approval of its CT:VQ™ imaging technology. The approval is expected to improve the diagnosis and monitoring of lung diseases, benefiting patients and healthcare providers by offering valuable insights into lung function without additional imaging or contrast agents.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company focused on revolutionizing respiratory care through advanced imaging and AI-powered solutions. The company provides insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases. Its patented XV Technology® and CT LVAS™ are key products that integrate seamlessly into existing hospital infrastructure via a Software as a Service (SaaS) model.
YTD Price Performance: -8.33%
Average Trading Volume: 945,688
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$182.2M
See more data about 4DX stock on TipRanks’ Stock Analysis page.